The role of adjuvant therapy after R0 resection for patients with intrahepatic and perihilar cholangiocarcinomas
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Young Saing | - |
dc.contributor.author | Oh, Sung Yong | - |
dc.contributor.author | Go, Se-Il | - |
dc.contributor.author | Kang, Jung-Hun | - |
dc.contributor.author | Park, Inkeun | - |
dc.contributor.author | Song, Haa-Na | - |
dc.contributor.author | Ji, Jun Ho | - |
dc.contributor.author | Hwang, In Gyu | - |
dc.contributor.author | Jang, Joung-Soon | - |
dc.date.available | 2020-02-27T19:45:16Z | - |
dc.date.created | 2020-02-07 | - |
dc.date.issued | 2017-01 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/6522 | - |
dc.description.abstract | There is still debated regarding the optimal treatment strategy for cholangiocarcinoma (CC) after curative resection. The aim of this study was to analyze the role of adjuvant therapy in R0-resected intrahepatic and perihilar CCs. We retrospectively reviewed the patients who underwent R0 resection for intrahepatic and perihilar CCs between January 2001 and December 2013 at six tertiary medical centers; adjuvant therapy consisted of chemotherapy (CT), chemoradiotherapy (CRT), or radiotherapy (RT). The outcomes of our study were recurrence-free survival (RFS) and overall survival (OS). We included a total of 137 consecutive patients in the analysis; 58.4% of them had intrahepatic CCs, and 25.5% had lymph node (LN) involvement. Seventy-three patients (53.3%) had received adjuvant therapy (CT, CRT, RT: 48, 13, 12, respectively), and most patients who had received adjuvant therapy had stage III or IVA, T3 or 4 tumors, and positive LNs. Multivariable analysis identified positive LN [hazard ratio (HR) 3.47; P < 0.001] and high baseline CA 19-9 level (HR 1.82; P = 0.027) as predictors of decreased OS. The effects of adjuvant therapy varied according to the treatment modality; adjuvant CRT showed significantly longer RFS than surgery only (HR 0.44; P = 0.036), with a nonsignificant trend for better OS (HR 0.46; P = 0.115). Adjuvant CT and RT were not associated with a survival advantage in R0-resected intrahepatic and perihilar CCs. CRT appears to be appropriate treatment after complete resection. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.relation.isPartOf | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.subject | BILIARY-TRACT CANCER | - |
dc.subject | EXTRAHEPATIC CHOLANGIOCARCINOMA | - |
dc.subject | HILAR CHOLANGIOCARCINOMA | - |
dc.subject | GALLBLADDER CARCINOMA | - |
dc.subject | SURGICAL RESECTION | - |
dc.subject | PROGNOSTIC-FACTORS | - |
dc.subject | GEMCITABINE | - |
dc.subject | RECURRENCE | - |
dc.subject | CHEMOTHERAPY | - |
dc.subject | RADIOTHERAPY | - |
dc.title | The role of adjuvant therapy after R0 resection for patients with intrahepatic and perihilar cholangiocarcinomas | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000392322700011 | - |
dc.identifier.doi | 10.1007/s00280-016-3206-4 | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, v.79, no.1, pp.99 - 106 | - |
dc.identifier.scopusid | 2-s2.0-85001759510 | - |
dc.citation.endPage | 106 | - |
dc.citation.startPage | 99 | - |
dc.citation.title | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.citation.volume | 79 | - |
dc.citation.number | 1 | - |
dc.contributor.affiliatedAuthor | Kim, Young Saing | - |
dc.contributor.affiliatedAuthor | Park, Inkeun | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Adjuvant therapy | - |
dc.subject.keywordAuthor | Chemotherapy | - |
dc.subject.keywordAuthor | Chemoradiotherapy | - |
dc.subject.keywordAuthor | Radiotherapy | - |
dc.subject.keywordAuthor | Intrahepatic cholangiocarcinoma | - |
dc.subject.keywordAuthor | Perihilar cholangiocarcinoma | - |
dc.subject.keywordAuthor | R0 resection | - |
dc.subject.keywordPlus | BILIARY-TRACT CANCER | - |
dc.subject.keywordPlus | EXTRAHEPATIC CHOLANGIOCARCINOMA | - |
dc.subject.keywordPlus | HILAR CHOLANGIOCARCINOMA | - |
dc.subject.keywordPlus | GALLBLADDER CARCINOMA | - |
dc.subject.keywordPlus | SURGICAL RESECTION | - |
dc.subject.keywordPlus | PROGNOSTIC-FACTORS | - |
dc.subject.keywordPlus | GEMCITABINE | - |
dc.subject.keywordPlus | RECURRENCE | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | RADIOTHERAPY | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.